Compass Therapeutics, Inc. (CMPX) Tops Q3 EPS by 3c

Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q3 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• ArcelorMittal Q2 2026 analyst consensus: $2.04B EBITDA expected
• TPU-As-A-Service could boost Google’s 2028 profit by over 15%: Barclays